How Much Does a Year of Health Care Cost in China Without Insurance?

Cross-Border Retirement Ledger, Part Two

If a 70-year-old retiree moves to China without Chinese health insurance and pays entirely out of pocket, how much should that person realistically budget for health care each year?

That is one of the first questions anyone considering self-funded health care in China needs to answer. “No health insurance” sounds inherently risky, especially to someone accustomed to the American health care system. But the financial significance of being uninsured ultimately depends on something more concrete: how much the medical care itself costs.

Looking at the price of a single CT scan or colonoscopy is not enough. A more realistic 70-year-old might see a doctor several times a year, undergo routine blood tests, take medications for hypertension or high cholesterol, and occasionally need a CT scan, MRI, or colonoscopy.

A better way to think about the question is therefore to build an annual “health care basket” and see what it actually costs.

This is not an attempt to calculate the average annual medical spending of an elderly person in China. Such an average would not necessarily tell us much about a retiree without Chinese insurance who pays cash for everything. Instead, consider a reasonably stable 70-year-old with one or two common chronic conditions who primarily uses public hospitals.

What might a normal—or even relatively busy—year of medical care actually cost?

Six Doctor Visits Are Not the Expensive Part

Consider the published 2026 prices at Shenzhen Integrated Chinese and Western Medicine Hospital, a public hospital.

A standard outpatient consultation costs RMB 25. Seeing an associate chief physician adds RMB 8, bringing the consultation to RMB 33, while a chief physician consultation costs RMB 50.

Suppose our 70-year-old retiree makes six outpatient visits during the year: four regular visits and two visits with an associate chief physician.

The total consultation cost would be just:

RMB 166.

For someone accustomed to American medical prices, that number immediately reveals something important about the economics of China’s public health care system: simply getting in the door to see a doctor is not where most of the money goes.

Routine laboratory testing is also relatively inexpensive.

A common set of follow-up tests for hypertension, high cholesterol, or mild diabetes might include a complete blood count, urinalysis, glucose, HbA1c, cholesterol and triglycerides, along with basic liver and kidney function tests.

Under current Shenzhen public-hospital pricing, a five-part differential blood count costs RMB 20, urinalysis RMB 9, glucose RMB 6, and HbA1c RMB 30. A basic lipid panel including total cholesterol, triglycerides, HDL, and LDL comes to about RMB 32. Urea is RMB 8, creatinine RMB 5, while common liver-function tests such as ALT, AST, GGT, and alkaline phosphatase are about RMB 5 each.

Put together, a fairly comprehensive round of routine chronic-disease laboratory testing comes to roughly RMB 140.

Do that twice a year, and the total is about RMB 280.

Six doctor visits plus two fairly comprehensive rounds of routine laboratory tests therefore add up to only a little over RMB 400.

For an otherwise stable retiree managing common chronic conditions, routine consultations and basic laboratory work are simply not the largest items in the annual health care budget.

Medication deserves much closer attention.

The Cost of Chronic Medication Can Vary Enormously

Medication is one part of the annual health care basket where averages can be misleading.

Two people with the same hypertension and high cholesterol can have very different annual drug costs depending on whether they use low-cost generic drugs purchased through China’s centralized procurement system or prefer original-brand medications.

A July 2026 government drug-price survey in Hanzhong, for example, listed Pfizer’s original-brand Lipitor, 20 mg atorvastatin, at about RMB 158.90 for 28 tablets. Pfizer’s Norvasc, 5 mg amlodipine, was about RMB 93 for 28 tablets.

If a retiree takes one tablet of each every day, roughly 13 boxes of each drug would be needed over a year.

That works out to approximately:

Lipitor: RMB 2,066 per year

Norvasc: RMB 1,209 per year

Together, the two original-brand medications cost about:

RMB 3,275 per year.

This is a useful benchmark because it deliberately does not rely on the cheapest available drugs. It assumes that a retiree with hypertension and high cholesterol chooses two familiar original-brand medications.

Generic alternatives can cost considerably less. In the same government price survey, domestically produced atorvastatin sold under the Ale brand by Beijing Jialin was roughly RMB 15–16 for seven 20 mg tablets. Metformin produced by Shanghai Sine, 0.25 g in a 60-tablet package, could be found at some surveyed pharmacies for only a few yuan.

That does not mean prescription drugs will always be inexpensive in China. A retiree who requires newer diabetes medications, anticoagulants, biologic drugs, or other expensive long-term therapies could face a very different budget.

For retirement planning, therefore, asking “Do I have chronic conditions?” is not specific enough.

A more useful question is:

Which drugs will I need to take for years, and what do those particular drugs cost in China?

For many common chronic conditions, that is a question that can be answered before making a retirement decision.

What If You Need a CT, an MRI, and a Colonoscopy in the Same Year?

Now make the year somewhat more medically active.

Under published Shenzhen public-hospital prices, a non-contrast CT scan of one body region costs RMB 231. A standard MRI of one region costs RMB 505. An electronic colonoscopy is listed at RMB 400, although anesthesia, pathology, polyp removal, medication, or other additional services can raise the final bill.

Suppose our retiree has the six doctor visits and two rounds of laboratory testing described above, takes Lipitor and Norvasc throughout the year, and also gets an ECG, a CT scan, an MRI, and a colonoscopy.

The annual basket would look like this:

Six outpatient consultations: RMB 166

Two rounds of routine laboratory testing: RMB 280

One year of two original-brand chronic medications: RMB 3,275

ECG: RMB 30

CT scan: RMB 231

MRI: RMB 505

Colonoscopy: RMB 400

Total:

approximately RMB 4,887.

A real medical bill would not stop neatly at RMB 4,887. A colonoscopy might require anesthesia or pathology. A CT or MRI might require contrast. There could be an ultrasound, X-ray, additional blood test, or short-term medication. Prices also vary among hospitals, pharmacies, and cities.

So RMB 4,887 should not be interpreted as a prediction that “a 70-year-old needs only RMB 4,887 a year for health care.”

What it gives us is a sense of scale.

We have deliberately constructed a relatively busy year: six doctor visits, two rounds of chronic-disease monitoring, two original-brand medications taken every day, plus an ECG, CT, MRI, and colonoscopy.

Yet the published base prices still add up to only about RMB 5,000.

For a retiree primarily using public hospitals who is not hospitalized and does not develop a major illness, an annual routine health care budget of RMB 10,000 therefore does not appear particularly tight. It leaves a substantial margin above the cost of this basket.

Hospitalization Is Where the Annual Budget Becomes Unpredictable

The calculation changes once hospitalization enters the picture.

A retiree might go several years without being admitted to a hospital and then suddenly spend time there because of pneumonia, an arrhythmia, a fall, or another illness.

Hospitalization cannot be modeled as neatly as a CT scan or a blood test. The final bill depends on the disease, length of stay, drugs, supplies, imaging, nursing care, and treatment required.

At the Shenzhen hospital used in our example, some of the basic charges remain quite low. An inpatient physician charge is RMB 60 per day. A two-person room costs RMB 90 per day and a three-person room RMB 69.

But those are only small components of a hospital bill. The illness and the treatment ultimately determine the cost.

This is why trying to squeeze hospitalization, cancer, surgery, and intensive care into an “average annual medical expense” can be misleading. It produces a number that looks precise while concealing the risk that actually matters.

A more useful retirement model separates medical spending into two pools.

The first covers frequent and relatively predictable expenses: doctor visits, laboratory tests, chronic medications, routine imaging, and procedures such as endoscopy. These can reasonably be managed through an annual health care budget.

The second covers less frequent but potentially much larger events: significant hospitalization, surgery, cancer, a heart attack, stroke, or intensive care. Those risks require a separate reserve for major illness.

Combining the two into a single annual average makes both harder to understand.

The U.S. Has a Very Different Cost Structure

Comparing this Chinese health care basket with the United States requires some care. It would make little sense to compare Chinese public-hospital cash prices with American hospitals’ uninsured sticker prices.

A more realistic 70-year-old American retiree has Medicare.

In 2026, the standard Medicare Part B premium is $202.90 per month, or about $2,435 per year, with an annual Part B deductible of $283.

Prescription coverage usually adds Medicare Part D. Part D premiums vary by plan and location, so there is no single premium paid by everyone. For 2026, CMS set the Part D base beneficiary premium at $38.99 per month. That is useful as a reference point rather than an estimate of what every beneficiary actually pays. The maximum Part D deductible for 2026 is $615, although individual plans may charge less or no deductible at all.

Using the base beneficiary premium simply as a benchmark, Part B and Part D premiums together would approach $2,900 a year—before the retiree actually goes to the doctor or fills a prescription.

Once medical care is used, Original Medicare generally pays most of the Medicare-approved amount for Part B services after the deductible, while the patient typically pays about 20 percent.

For example, Medicare’s 2026 procedure-price data show average patient costs of roughly $32 to $42 for a non-contrast head CT, depending on the setting. A colonoscopy with biopsy can leave the patient with an average cost of about $166 in a non-hospital surgical center, and more in a hospital outpatient department. Prescription drugs generate their own cost sharing under the retiree’s Part D plan.

The difference between the two countries, therefore, is not simply what a CT scan or colonoscopy costs.

In the United States, retirees generally pay recurring insurance premiums first and then incur deductibles, copayments, or coinsurance when they use medical services. A retiree paying cash in China does not have that layer of recurring insurance premiums, but must pay directly whenever medical care is used.

American insurance can absorb much of the cost of many serious illnesses. But that does not mean retirees have no medical expenses, nor does it mean every financial risk of aging is unconditionally covered.

The advantage of self-paying in China is different: many ordinary medical services have relatively low cash prices.

The meaningful comparison is therefore between two different ways of carrying health care risk—not simply a contest over which country has the cheaper doctor visit.

So Is $1,500 a Year Enough?

We can now return to the assumption used in the broader Cross-Border Retirement Ledger model: $1,500 per person per year for routine medical expenses in China.

At a planning exchange rate of RMB 6.7 to the dollar, that is roughly RMB 10,000 a year.

Based on the health care basket above, that figure does not appear unusually low for a retiree who primarily uses Chinese public hospitals, has one or two common chronic conditions, and does not require expensive specialty drugs on a continuing basis.

Six doctor visits, two rounds of chronic-disease laboratory testing, a full year of two original-brand medications, and an ECG, CT, MRI, and colonoscopy together come to a base cost of approximately RMB 4,887.

Even after allowing additional room for anesthesia, pathology, temporary medications, extra tests, and differences among hospitals and regions, RMB 10,000 still provides a meaningful cushion.

But there is an essential boundary to that conclusion.

$1,500 a year is not an estimate of a retiree’s total medical risk.

It is a budget for routine years.

A substantial hospitalization can push spending beyond that amount. Cancer, cardiovascular intervention, stroke, major surgery, or intensive care belongs in an entirely different financial category.

A useful retirement model therefore should not ask only, “How much does an elderly person spend on health care in an average year?”

It should ask two separate questions.

How much cash is needed for ordinary medical care each year?

And how much additional capital is needed when a serious illness actually occurs?

We now have a much better basis for answering the first question.

For a retiree paying entirely out of pocket and relying primarily on China’s public hospitals, an annual routine medical reserve of roughly RMB 10,000—or about $1,500 at our planning exchange rate—appears to have a reasonable foundation in current prices.

The second question is much harder.

What happens if that same retiree develops cancer, suffers a heart attack or stroke, or spends time in intensive care?

That is where the financial viability of retiring in China without Chinese health insurance will face its more important test.

This article is part of Chinese Voices’ “Cross-Border Retirement Ledger” series. Rather than asking which country is “better” for retirement, the series looks at health care, long-term care, income, and assets to examine the financial risks of cross-border retirement—one calculation at a time.

By Voice in Between